Dual Antiplatelet Therapy: A Concise Review of Evidence for the Practicing Clinician

This review article examines the importance of dual antiplatelet therapy (DAPT) in managing thrombotic events related to cardiovascular atherosclerotic disease. DAPT typically includes aspirin and a P2Y12 inhibitor and is used to mitigate complications from cardiovascular atherosclerotic disease. The article details the pharmacological profiles of common antiplatelet agents. Evidence from randomized controlled trials informs DAPT's application in various clinical contexts, demonstrating clear benefits in chronic coronary syndrome and acute coronary syndrome. However, its role in primary prevention is unproven. The review highlights the need for individualized treatment strategies, particularly concerning the duration of therapy following procedures like percutaneous coronary intervention, coronary artery bypass grafting and post transcatheter aortic valve implantation. Considering the ubiquitousness of these medications clinicians should be aware of the underlying induction, and evidence surrounding their use. Ongoing research is essential to refine antiplatelet strategies, ultimately improving patient outcomes while minimizing adverse effects. This review highlights the importance of individualized assessments in optimizing DAPT for various cardiovascular conditions.